U.S. Beverage Stock News

NYSE:PEB
NYSE:PEBHotel and Resort REITs

A Look At Pebblebrook Hotel Trust (PEB) Valuation After Recent Share Price Strength

Pebblebrook Hotel Trust stock moves draw investor focus Pebblebrook Hotel Trust (PEB) is back on many investors’ radars after a recent stretch of positive share price performance, with the stock up over the past month and past 3 months. See our latest analysis for Pebblebrook Hotel Trust. That recent upswing fits into a broader recovery story, with a 30 day share price return of 13.88% and a 1 year total shareholder return of 53.71% pointing to improving momentum despite a weak 5 year total...
NYSE:CC
NYSE:CCChemicals

Assessing Chemours (CC) Valuation After Q1 Earnings Beat And Reaffirmed Guidance

Why Chemours stock is on investors’ radar Chemours (CC) has drawn fresh attention after its first quarter 2026 earnings, where several business segments outperformed expectations, and management highlighted debt reduction, refinancing activity, and reaffirmed full year sales and EBITDA guidance. See our latest analysis for Chemours. That interest has come against a sharp pullback in recent days, with a 1 day share price return of 5.32% decline and a 7 day share price return of 16.85% decline,...
NYSE:SCL
NYSE:SCLChemicals

How Stepan’s Swing to Q1 Loss With Steady Dividend At Stepan (SCL) Has Changed Its Investment Story

Stepan Company reported past first-quarter 2026 results showing sales of US$604.51 million versus US$593.26 million a year earlier, but it swung from net income of US$19.71 million to a net loss of US$41.41 million, with basic and diluted loss per share from continuing operations of US$1.81 compared with earnings of US$0.86. Despite the move into loss-making territory, Stepan maintained its shareholder payout by affirming a quarterly dividend of US$0.395 per share, payable on June 15, 2026,...
NasdaqGS:KHC
NasdaqGS:KHCFood

Kraft Heinz (KHC) Is Up 6.5% After Q1 Beat, Buybacks And Debt Tender - What's Changed

The Kraft Heinz Company recently reported first-quarter 2026 results, with sales of US$6,047 million, net income of US$798 million, basic EPS of US$0.67, a US$13 million goodwill and intangible impairment, and affirmed a quarterly dividend of US$0.40 per share payable on June 26, 2026. Alongside early progress in its turnaround under new CEO Steve Cahillane, the company has completed a US$1.51 billion share repurchase program and launched a US$1.10 billion tender offer to reshape its...
NYSE:DOCS
NYSE:DOCSHealthcare Services

Assessing Doximity (DOCS) Valuation As Analyst Forecasts Shift Before Key Earnings Release

Doximity (DOCS) is back in focus after its share price reacted to shifting analyst forecasts ahead of the upcoming earnings release, with investors weighing expectations for lower EPS against modest revenue growth. See our latest analysis for Doximity. The stock has staged a short term rebound, with a 7 day share price return of 6.51% and a 30 day share price return of 15.69%. However, this sits against a year to date share price return decline of 39.87% and a 1 year total shareholder return...
NasdaqGS:SBCF
NasdaqGS:SBCFBanks

Will Rising Net Interest Income And Share Buybacks Change Seacoast Banking Corporation of Florida's (SBCF) Narrative

In April 2026, Seacoast Banking Corporation of Florida reported first-quarter 2026 results, with net interest income rising to US$176.47 million from US$118.52 million a year earlier, while net income was broadly flat at US$31.9 million and diluted EPS from continuing operations eased to US$0.29 from US$0.37. Over the same quarter, Seacoast also completed a buyback of 317,628 shares for US$10.23 million, a small but clear signal of ongoing capital return alongside its mixed earnings...
NasdaqGS:DXPE
NasdaqGS:DXPETrade Distributors

Is DXP Enterprises (DXPE) Quietly Recasting Its Strategy Around Water-Focused, Acquisition-Driven Growth?

In the past week, DXP Enterprises, Inc. reported Q1 2026 results with sales rising to US$521.66 million, while net income edged down to US$19.98 million compared with the prior year. Beneath the headline growth, the Innovative Pumping Solutions segment and recent acquisitions drove nearly 10% higher revenue and deeper exposure to the water and wastewater market. Next, we’ll examine how this acquisition-fueled, water-focused growth alongside a slight earnings miss affects DXP Enterprises’...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

The Bull Case For Duolingo (DUOL) Could Change Following Sharper Q1 Profitability And Raised EBITDA Guidance

In early May 2026, Duolingo, Inc. reported first-quarter 2026 results showing sales of US$291.97 million and net income of US$43.46 million, with both basic and diluted earnings per share from continuing operations increasing compared with the prior year. Beyond the headline growth, Duolingo’s results highlighted stronger profitability, continued expansion into new subjects like Chess and Math, and a user-engagement focus that aims to balance monetization with long-term platform health. With...
NYSE:IHS
NYSE:IHSTelecom

IHS Holding Sells I‑Systems Stake And Refocuses On Core Tower Assets

IHS Holding (NYSE:IHS) has completed the divestment of its 51% stake in Brazilian fiber infrastructure venture I-Systems. The stake has been sold to TIM S.A., marking IHS Holding's exit from this Brazilian optical fiber joint venture. IHS Holding, trading at $8.23, has seen its stock return 12.0% year to date and 44.1% over the past year, while its 3 year return stands at 9.2%. This completed I-Systems divestment gives investors a fresh development to consider alongside those share price...
NasdaqGS:MMSI
NasdaqGS:MMSIMedical Equipment

Is Merit Medical Systems (MMSI) Pricing Look Attractive After Steep One Year Share Price Slide

If you are wondering whether Merit Medical Systems is starting to look interesting at its current share price, this article focuses squarely on what that price might imply about value. The stock last closed at US$62.33, with recent returns of an 8.6% decline over 7 days, a 7.5% decline over 30 days, a 27.9% decline year to date, and a 35.1% decline over the past year. These moves have put the stock back on many watchlists, as investors reassess what they are willing to pay for medical...
NasdaqGS:NCNO
NasdaqGS:NCNOSoftware

The Bull Case For nCino (NCNO) Could Change Following Major European Lending Platform Win

nCino recently won significant banking clients, including being selected by Raiffeisenbankengruppe Oesterreich as its unified corporate lending platform and by Vision Credit Union to modernize agricultural and commercial lending with AI-enabled tools. These client wins, alongside new leadership appointments such as a Chief Revenue Officer and Asia-Pacific Managing Director, highlight nCino’s push to deepen international reach and scale its AI-focused banking platform. We’ll now look at how...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Evaluating Clover Health Investments (CLOV) Valuation After A Sharp Short‑Term Share Price Rebound

What recent performance says about Clover Health Investments (CLOV) Clover Health Investments (CLOV) has attracted fresh attention after a sharp share price move, with the stock showing a 5.2% gain over the past day and a 48.4% gain over the past month. See our latest analysis for Clover Health Investments. The recent 48.4% 1-month share price return sits against a 17.0% share price return year to date and a 24.8% decline in the 1-year total shareholder return. This points to momentum...
NYSE:JBL
NYSE:JBLElectronic

A Look At Jabil (JBL) Valuation As Earnings Optimism And Analyst Upgrades Draw Fresh Attention

Jabil (JBL) is back in focus as investors look ahead to its upcoming earnings report, with expectations for higher earnings per share and revenue helping to fuel fresh interest in the stock. See our latest analysis for Jabil. The recent 1-day share price return of -6.11% to US$349.60 comes after a 30-day share price return of 28.13% and a 1-year total shareholder return of 126.78%. This points to strong momentum with some short term volatility as investors position around earnings...
NYSE:ALB
NYSE:ALBChemicals

Albemarle Votes Reshape Governance While Dividend And Cash Flows Steady

Albemarle (NYSE:ALB) held its annual shareholder meeting on May 5, 2026. Shareholders approved the board slate, executive compensation package, and auditor ratification. A proposal to remove supermajority provisions for certain affiliated transactions narrowly did not pass. Shareholders backed a proposal to make it easier for investors to call special meetings. Albemarle, a major producer in the lithium and specialty chemicals space, sits at the center of debates around corporate governance...
NYSE:LYV
NYSE:LYVEntertainment

Is Q1 2026 Legal Accrual-Driven Loss Altering The Investment Case For Live Nation (LYV)?

In the first quarter of 2026, Live Nation Entertainment reported sales of US$3,793.03 million, but a net loss of US$389.1 million as a US$450 million legal accrual tied to investigations and litigation pushed the company into an operating loss. At the same time, the long-running Popp v. Live Nation and Ticketmaster nationwide class action over allegedly supracompetitive ticketing fees advanced, while management emphasized double-digit adjusted operating income growth expectations and record...
NYSE:EHC
NYSE:EHCHealthcare

A Look At Encompass Health (EHC) Valuation After Guidance Upgrade And Expansion Plans

Encompass Health (EHC) stock is in focus after first quarter 2026 results topped Wall Street expectations, management raised full year revenue and adjusted EPS guidance, and the company continued expanding its inpatient rehabilitation hospital network. See our latest analysis for Encompass Health. The recent 1 day share price return of 2.0% to $107.15 and 7 day share price return of 7.2% suggest momentum has picked up following the earnings beat, higher guidance, new hospital opening and...
NYSE:EPR
NYSE:EPRSpecialized REITs

How EPR’s Regional Parks Bet and Higher Spending Plans Could Reshape EPR Properties (EPR) Investors

EPR Properties’ recently reported first-quarter 2026 results showed revenue rising to US$181.25 million and funds from operations growth, even as net income and earnings per share edged lower compared with a year earlier. Alongside the earnings, EPR closed or advanced a US$315.00 million acquisition of a Seven Flags regional attractions portfolio and lifted its annual investment spending plans, underscoring management’s commitment to experiential real estate expansion and portfolio...
NYSE:JPM
NYSE:JPMBanks

Will JPMorgan’s AI Bond-Trading and Tokenization Push Change JPMorgan Chase’s (JPM) Narrative

In recent days, LTX, an AI-powered corporate bond e-trading venue backed by Broadridge, announced that J.P. Morgan joined as a fully integrated liquidity provider, while JPMorgan Chase expanded its fixed-income issuance, rolled out new youth-focused banking tools, and deepened partnerships in data, private credit and tokenized settlement. Together, these moves highlight JPMorgan’s push to shape next-generation bond and digital markets even as CEO Jamie Dimon publicly flags risks of a...
NYSE:USFD
NYSE:USFDConsumer Retailing

A Look At US Foods Holding (USFD) Valuation After Recent Share Price Pullback

Assessing US Foods Holding after recent returns Without a single defining news headline, US Foods Holding (USFD) has still drawn attention after recent share performance, with the stock showing a 5.6% decline over the past day and a 7.1% slide over the past week. Those short term moves sit alongside a smaller month pullback of 2.8% and a 3 month decline of 3.8%. The stock remains up 16.4% year to date and 20.9% over the past year. See our latest analysis for US Foods Holding. The recent 1 day...
NYSE:ABT
NYSE:ABTMedical Equipment

Is It Time To Reconsider Abbott Laboratories (ABT) After The Recent Share Price Slump?

This article examines whether Abbott Laboratories could be presenting a value opportunity after a difficult period in the market, and breaks down what the current share price might be offering. The stock last closed at US$87.01. Recent returns show a 4.2% decline over 7 days, a 14.6% decline over 30 days, and a 29.9% decline year to date, including a 33.7% decline over the past year. These moves mean many holders are reassessing what they are paying for. Recent news coverage has discussed...
NYSE:PAGS
NYSE:PAGSDiversified Financial

Evaluating PagSeguro Digital (PAGS) Valuation As Earnings Growth Expectations Clash With Cut Analyst Estimates

Upcoming earnings and current sentiment Market attention is centering on PagSeguro Digital (PAGS) ahead of its upcoming quarterly results, with expectations for year-over-year growth in earnings and revenue, but recent estimate cuts are adding a layer of uncertainty for investors. See our latest analysis for PagSeguro Digital. PagSeguro Digital's share price has been choppy, with a 2.79% one day decline and a 7.92% 90 day share price return. The 1 year total shareholder return of 9.61%...
NYSE:MMS
NYSE:MMSProfessional Services

Has The Market Mispriced Maximus (MMS) After Its Recent 22.9% Year-To-Date Decline?

Wondering if Maximus stock is offering fair value or a potential bargain right now, especially after a tough stretch for returns. The share price last closed at US$66.66, with Maximus delivering a 1.6% return over the past week and 2.3% over the last month, but a 22.9% decline year to date and a 10.6% decline over the last year hint at changing sentiment. Recent coverage has focused on how Maximus fits into investors' long term portfolios and whether the current price reflects its...
NasdaqGS:LQDT
NasdaqGS:LQDTCommercial Services

Assessing Liquidity Services (LQDT) Valuation As Recent Share Price Momentum Draws Attention

Why Liquidity Services stock is back on investor radars Liquidity Services (LQDT) has caught investor attention after a period of solid share price momentum over the past month and past 3 months, prompting a closer look at its current valuation. See our latest analysis for Liquidity Services. While the 1 day share price return of Liquidity Services has recently dipped 2.61%, a 30 day share price return of 14.90% and 22.51% year to date, alongside a 3 year total shareholder return of 135.54%,...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO?

In late April 2026, NeoGenomics, Inc. raised its full‑year 2026 revenue guidance to US$797.0 million–US$803.0 million and reported first‑quarter sales of US$186.67 million with a narrower net loss of US$17.11 million compared with a year earlier. The combination of stronger quarterly performance and higher revenue expectations suggests the company’s oncology testing business is gaining traction, even as it remains loss‑making. We’ll now examine how NeoGenomics’ higher 2026 revenue outlook...